A detailed history of Morgan Stanley transactions in Immunic, Inc. stock. As of the latest transaction made, Morgan Stanley holds 390,710 shares of IMUX stock, worth $421,966. This represents 0.0% of its overall portfolio holdings.

Number of Shares
390,710
Previous 25,404 1437.99%
Holding current value
$421,966
Previous $28,000 2200.0%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.08 - $1.95 $394,530 - $712,346
365,306 Added 1437.99%
390,710 $644,000
Q2 2024

Oct 17, 2024

SELL
$0.98 - $1.44 $4,806 - $7,063
-4,905 Reduced 16.18%
25,404 $28,000
Q2 2024

Aug 14, 2024

SELL
$0.98 - $1.44 $4,806 - $7,063
-4,905 Reduced 16.18%
25,404 $28,000
Q1 2024

Oct 17, 2024

BUY
$1.14 - $1.53 $5,591 - $7,504
4,905 Added 19.31%
30,309 $40,000
Q1 2024

Aug 16, 2024

BUY
$1.14 - $1.53 $15,873 - $21,303
13,924 Added 84.98%
30,309 $40,000
Q1 2024

May 15, 2024

BUY
$1.14 - $1.53 $15,873 - $21,303
13,924 Added 84.98%
30,309 $40,000
Q4 2023

Aug 16, 2024

SELL
$0.97 - $1.6 $8,748 - $14,430
-9,019 Reduced 35.5%
16,385 $24,000
Q4 2023

Feb 13, 2024

SELL
$0.97 - $1.6 $15,237 - $25,134
-15,709 Reduced 48.95%
16,385 $24,000
Q3 2023

Nov 15, 2023

SELL
$1.35 - $2.87 $33,764 - $71,781
-25,011 Reduced 43.8%
32,094 $47,000
Q2 2023

Aug 14, 2023

SELL
$1.33 - $2.51 $621,602 - $1.17 Million
-467,370 Reduced 89.11%
57,105 $143,000
Q1 2023

May 15, 2023

BUY
$1.35 - $2.87 $67,632 - $143,781
50,098 Added 10.56%
524,475 $781,000
Q4 2022

Feb 14, 2023

BUY
$1.13 - $10.8 $515,835 - $4.93 Million
456,492 Added 2552.37%
474,377 $664,000
Q3 2022

Nov 14, 2022

SELL
$3.0 - $5.49 $64,056 - $117,222
-21,352 Reduced 54.42%
17,885 $56,000
Q2 2022

Oct 27, 2022

BUY
$3.13 - $12.25 $48,286 - $188,980
15,427 Added 64.79%
39,237 $136,000
Q2 2022

Aug 15, 2022

BUY
$3.13 - $12.25 $48,286 - $188,980
15,427 Added 64.79%
39,237 $136,000
Q1 2022

Oct 27, 2022

SELL
$9.54 - $14.26 $147,173 - $219,989
-15,427 Reduced 39.32%
23,810 $269,000
Q1 2022

May 13, 2022

SELL
$9.54 - $14.26 $337,792 - $504,918
-35,408 Reduced 59.79%
23,810 $269,000
Q4 2021

Feb 14, 2022

BUY
$7.34 - $10.25 $355,498 - $496,438
48,433 Added 449.08%
59,218 $567,000
Q3 2021

Nov 15, 2021

BUY
$8.05 - $13.29 $86,819 - $143,332
10,785 New
10,785 $95,000

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $33M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.